Table 2. Overview of studies investigating phosphate (A) and FGF23 (B) in relation to clinical outcomes in diabetes.
| Author | n | Follow-up (years) | Age (years) | eGFR (ml/min/1.73 m2) | Phosphate (mg/dl) | Outcome: hazard ratio (95% CI)1 |
|---|---|---|---|---|---|---|
| (A) | ||||||
| Silva et al. | 107 | 2.8 ± 0.7 | 57.2 ± 7.1 | 52.89 ± 20.15 | 3.99 ± 0.85 | CV mortality 1.08 (1.02–3.41) |
| Silva et al. | 119 | 76 months | 62.6 ± 12.1 | 44.9 ± 25.2 | 4.32 ± 1.19 | CV mortality: 1.44 (1.16–3.52) |
| Choncol et al. | 950 | 4.8 ± 1.3 | 57.9 ± 8.4 | 67.0 (18.5) | 3.6 ± 0.52 | CV mortality: 5.00 (1.70–14.72) |
| Author | n | Follow-up (years) | Age (years) | eGFR (ml/min/1.73 m2) | FGF23 (RU/ml) | Outcome: hazard ratio (95% CI)1 |
|---|---|---|---|---|---|---|
| (B) | ||||||
| Silva et al. | 107 | 2.8 ± 0.7 | 57.2 ± 7.1 | 52.89 ± 20.15 | 135.0 ± 135.2 | CV mortality: 2.05 (1.01–8.25) |
| Titan et al. | 55 | 2.6 ± 0.8 | 58.4 ± 10.0 | 53.0 ± 20.6 | 92.0 ± 42.9 | Composite endpoint2: 1.09 (1.01–1.16) |
| Tuñón et al. | 173 | 2.15 ± 0.99 | 62.8 | 73.75 ± 20.84 | 72.2 (56.7–104.9) | Composite endpoint3: 1.27 (1.13–1.43) |
| Yeung et al. | 310 | 5.8 (3.3–6.5) | 61.5 ± 8.7 | 88.5 ± 14.8 | 84.2 (67.0–117.6) | All-cause mortality: 2.55 (1.58–4.10) |
| MACE: 1.68 (1.08–2.61) | ||||||
| Frimodt et al. | 200 | 6.1 (5.9–6.6) | 59.9 ± 9 | 91.1 ± 18.3 | 71 (52–108) | All-cause mortality: 1.57 (1.11–2.18) |
| Chan et al. | 513 | 6.6 (5.8–7.5) | 55.0 (49.0–62.0) | 91.3 (76.4–111.3) | 112.4 (79.0–165.8) | All-cause mortality: 1.74 (1.44–2.09) |
1
Adjusted for potential confounders.
2
Composite endpoint of all-cause mortality, doubling of serum creatinine, or requirement for dialysis.
3
Composite endpoint of acute ischemic events (acute coronary syndrome, stroke, or transient ischemic attack), heart failure, or death.
Abbreviations: CI, confidence interval; CV, cardiovascular; MACE, major adverse cardiac event.